Want to see CYTK full AI Analyst Report?
CYTK Stock Chart & Stats
$79.20
$0.81(1.01%)
At close: 4:00 PM EDT
$79.20
$0.81(1.01%)
Day’s Range― - ―
52-Week Range$58.05 - $88.31
Previous CloseN/A
Volume899.92K
Average Volume (3M)1.97M
Market Cap
$8.76B
Enterprise Value$11.35B
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Nov 04, 2026EPS Estimate
-1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.21
Shares Outstanding139,023,420
10 Day Avg. Volume1,316,578
30 Day Avg. Volume1,969,284
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)-11.56
Price to Sales (P/S)86.62
P/FCF Ratio-14.26
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue160.01
Enterprise Value/Gross Profit180.29
Enterprise Value/Ebitda-13.82
Forecast
1Y Price Target
$108.23Price Target Upside36.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-6.03
Revenue Forecast (FY)$153.21M
Bulls Say, Bears Say
Bulls Say
MYQORZO Commercial AdoptionRapid growth in dispensed patients, prescriber reach, and product revenue indicates that MYQORZO is gaining early commercial traction. Continued adoption would diversify Cytokinetics beyond collaboration economics and establish a foundation for recurring product revenue as market access expands.
Late-Stage Clinical And Regulatory ProgressPositive pivotal data in non-obstructive HCM could expand aficamten’s addressable patient population beyond its current use case. The planned supplemental filing and existing MAPLE-HCM review create multiple regulatory milestones that may support broader commercialization over the next several quarters.
Strengthened LiquidityThe financing materially increases resources available for commercialization, regulatory filings, and late-stage clinical programs. A larger cash position provides greater flexibility to fund the pipeline and launch activities while reducing the immediate pressure created by the company’s substantial operating expenditures.
Bears Say
Revenue Volatility And DeclineThe sharp year-over-year decline shows that reported revenue remains highly dependent on irregular licensing and milestone payments rather than a broad, stable commercial base. Product growth may improve the mix, but near-term results can remain volatile when collaboration milestones do not recur.
Heavy Cash Burn And Persistent LossesLarge recurring cash outflows and sustained net losses require Cytokinetics to fund operations while commercialization and development programs scale. Continued burn can consume liquidity faster than product revenue builds, increasing the importance of disciplined spending and future financing capacity.
Pressured Capital StructureNegative equity combined with substantial debt indicates limited balance-sheet resilience relative to a stable issuer. This structure can constrain financial flexibility, increase reliance on capital markets, and leave less room to absorb delays in approvals, launches, or revenue growth.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $58.05 and its highest was $88.31 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $8.76B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -$1.5 earnings per share for the quarter, beating the consensus estimate of -$1.628 by $0.128.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.44.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 139,023,420 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.5 in its last earnings report, beating expectations of -$1.628. Following the earnings report the stock price went down -5.665%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$108.23 (36.66% Upside)
$108.23 (36.66% Upside)
Blogger Sentiment
Neutral
CYTK Sentiment 50%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 596.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.18%
12-Months-Change
Fundamentals
Return on Equity
163.98%
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$108.23
▲(36.66% Upside)
Technical Analysis
Sarepta Therapeutics
―
PTC Therapeutics
―
Scholar Rock Holding
―
Dyne Therapeutics
―
Edgewise Therapeutics
―
Ownership Overview
0.63% Insiders
36.09% Mutual Funds
1.11% Other Institutional Investors
36.23% Public Companies and
Individual Investors